Organogenesis (ORGO) Holdings announced plans to expand manufacturing capacity with a long-term lease for a 122,000-square foot state-of-the-art biomanufacturing facility located at 100 Technology Way in Smithfield, Rhode Island. “We are pleased to join the Rhode Island life sciences community as we expand our New England manufacturing capacity to support future growth,” said Gary S. Gillheeney, Sr., President, Chief Executive Officer, and Chair of the Board. “We look forward to strengthening our industry-leading portfolio with this world class biomanufacturing facility.” The company will continue to operate its headquarters and manufacturing facilities in Canton, Mass., as well as additional operations in Norwood, Mass., Birmingham, Ala., San Diego, Calif., St. Petersburg, Fla., and Reinach, Switzerland. The Rhode Island lease is contingent upon anticipated state and local tax incentives.
Don't Miss our Black Friday Offers:
- Unlock your investing potential with TipRanks Premium - Now At 40% OFF!
- Make smarter investments with weekly expert stock picks from the Smart Investor Newsletter
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See Insiders’ Hot Stocks on TipRanks >>
Read More on ORGO:
- Organogenesis ‘commends’ final local coverage determinations
- Organogenesis Holdings Secures $130M Investment for Growth
- Organogenesis Reports Robust Third Quarter Growth
- Organogenesis reports Q3 EPS 9c, consensus (1c)
- Organogenesis sees FY24 revenue $455-$480M, consensus $456.15M
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
